TrialPath
Recruiting

Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

NCT07868939 · Viking Therapeutics, Inc.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight
About this study
This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.
Eligibility criteria
Inclusion Criteria: 1. Age ≥18 years of age at the time of signing the informed consent. 2. Body mass index (BMI) ≥ 27 kg/m2 3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. Exclusion Criteria: 1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation 2. Self-reported body weight change of 5% or more within 3 months of screening 3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed \>1 year prior to screening) 4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line) 5. Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM) 6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening • Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG \< 54 mg/dL. 7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \> 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization 8. Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6. 9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) 10. History of acute or chronic pancreatitis 11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.
Study design
Enrollment target: 560 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2026-11
Estimated completion: 2028-12
Last updated: 2026-11-16
Interventions
Drug: VK2735 OralDrug: Placebo Comparator
Primary outcomes
  • • Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily (68 weeks)
Sponsor
Viking Therapeutics, Inc. · industry
Contacts & investigators
ContactHubert Chen, MD · contact · clinicaltrials@vikingtherapeutics.com · 8587044660
All locations (19)
Viking Clinical Site #2020Recruiting
Tucson, Arizona, United States
Viking Clinical Site #2015Recruiting
Lake Forest, California, United States
Viking Clinical Site #2059Recruiting
Ocoee, Florida, United States
Viking Clinical Site #2013Recruiting
Atlanta, Georgia, United States
Viking Clinical Site #2001Recruiting
Evansville, Indiana, United States
Viking Clinical Site #2046Recruiting
Indianapolis, Indiana, United States
Viking Clinical Site #2009Recruiting
Valparaiso, Indiana, United States
Viking Clinical Site #2004Recruiting
Richfield, Minnesota, United States
Viking Clinical Site #2029Recruiting
Jackson, Mississippi, United States
Viking Clinical Site #2028Recruiting
Springfield, Missouri, United States
Viking Clinical Site #2052Recruiting
Albuquerque, New Mexico, United States
Viking Clinical Site #2039Recruiting
Binghamton, New York, United States
Viking Clinical Site #2023Recruiting
Medford, Oregon, United States
Viking Clinical Site #2002Recruiting
East Greenwich, Rhode Island, United States
Viking Clinical Site #2044Recruiting
Charleston, South Carolina, United States
Viking Clinical Site #2030Recruiting
Hendersonville, Tennessee, United States
Viking Clinical Site #2031Recruiting
Abilene, Texas, United States
Viking Clinical Site #2011Recruiting
Seattle, Washington, United States
Viking Clinical Site #2042Recruiting
Spokane, Washington, United States